Chiesi/Aptuit deal for idiopathic pulmonary fibrosis treatment

Aptuit and Chiesi Farmaceutici announced they have entered into an agreement under which Aptuit will conduct a Discovery Project aimed at providing innovative drugs to treat idiopathic pulmonary fibrosis. Both Aptuit and Chiesi will contribute scientifically. Atpuit sold its clinical trial support business to Catalent in 2011 for $410m, then completed two acquisitions in 2016—Exquiron Biotech and Kuecept. The CRO has facilities in the UK, Italy, and Switzerland and focuses on neurosciences, oncology and on the respiratory and infectious diseases areas.
(Source Aptuit press release)